Literature DB >> 6810283

[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

A Thabaut, J L Durosoir.   

Abstract

The MIC of the four quinolones were determined for 839 bacterial isolates. The mean in vitro activity of pefloxacin against strains susceptible to nalidixic acid was found to be four times greater than flumequin, eight times greater than pipemidic acid, sixteen times greater than nalidixic acid. On resistant strains pefloxacin, at levels lower than 32 micrograms/ml, remained active against 67 go 100 per cent of the strains as a function of bacterial species. Streptocoques D and Pseudomonas aeruginosa, resistant to other quinolones, were found to be susceptible to pefloxacin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810283

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  13 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.

Authors:  P Van der Auwera; J Klastersky; S Lieppe; M Husson; D Lauzon; A P Lopez
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Pharmacokinetics of pefloxacin in renal insufficiency.

Authors:  G Montay; C Jacquot; J Bariety; R Cunci
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 8.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

9.  Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.

Authors:  E Sultan; C Richard; M Pezzano; P Auzepy; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.

Authors:  F M Gordin; C J Hackbarth; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.